Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder

References

• Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003;2:104-13
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Revised 4th edn. Washington, DC: American Psychiatric Press, 2000
   Google Scholar
• Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry 1998;59(Suppl. 7):50-8
   PubMed Web of Science ®Google Scholar
• Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005;57:1215-20
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Faraone SV. Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder. J Pediatr 1998;133:544-51
   PubMed Web of Science ®Google Scholar
• Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127-52
   PubMed Web of Science ®Google Scholar
• Banaschewski T, Roessner V, Dittmann RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004;13(Suppl. 1):i102-16
   PubMedGoogle Scholar
• Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711
   PubMed Web of Science ®Google Scholar
• Prasad S. A new paradigm for developing drugs in children: atomoxetine as a model. Arch Dis Child 2005;90(Suppl. 1):i13-16
   PubMed Web of Science ®Google Scholar
• Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:e1-8
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-20
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901
   PubMed Web of Science ®Google Scholar
• Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:e83
   PubMed Web of Science ®Google Scholar
• Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-7
   PubMed Web of Science ®Google Scholar
• Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005;65:1941-9
   PubMed Web of Science ®Google Scholar
• Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007;17:407-20
   PubMed Web of Science ®Google Scholar
• Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007;46:1119-27
   PubMed Web of Science ®Google Scholar
• Svanborg P, Thernlund G, Gustafsson PA et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder – a randomized, double-blind, placebo-controlled study in stimulant-naïve children and adolescents. Eur Child Adolesc Psychiatry 2009;18:240-9
   Google Scholar
• Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008;165:721-30
   PubMed Web of Science ®Google Scholar
• Ulloa RE, Ortiz S, Higuera F, et al. Interrater reliability of the Spanish version of Schedule for Affective Disorders and Schizophrenia for School-Age Children – Present and Lifetime version (K-SADS-PL). Actas Esp Psiquiatr 2006;34:36-40
   PubMed Web of Science ®Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, Norms and Clinical Interpretation. Spiral-bound edn. New York: The Guilford Press, 1998
   Google Scholar
• Conners CK. Conners’ Rating Scales-Revised: Technical Manual. Toronto: Multi-Health Systems, 1997
   Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology, revised version. Bethesda, MD: US Department of Health, Education and Welfare, 1976
   Google Scholar
• Riley AW, Forrest CB, Rebok GW, et al. The Child Report Form of the CHIP-Child Edition: reliability and validity. Med Care 2004;42:221-31
   PubMed Web of Science ®Google Scholar
• Riley AW, Forrest CB, Starfield B, et al. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care 2004;42:210-20
   PubMed Web of Science ®Google Scholar
• McCulloch CE, Searle SR. Generalized, Linear and Mixed Models, 1st edn. New York, NY: Wiley–Interscience, 2001
   Google Scholar
• Westfall P, Krishen A. Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. J Stat Plan Inference 2001;99:25-40
   Web of Science ®Google Scholar
• Rosnow RL, Rosenthal R. Computing contrasts, effect sizes, and counternulls on other people's published data: general procedures for research consumers. Psychol Methods 1996;1:331-40
   Web of Science ®Google Scholar
• Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:919-27
   PubMed Web of Science ®Google Scholar
• Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 2006;149:112-19
   PubMed Web of Science ®Google Scholar
• Dickson RA, Lee B, Turgay A et al. Change in ADHD Symptoms During 1 Year of Atomoxetine Treatment. Poster presented at: 57th Annual Meeting of the Canadian Psychiatric Association; 2007. Montreal, Canada, 2007
   Google Scholar
• Zhang J, Quan H, Ng J, Stepanavage ME. Some statistical methods for multiple endpoints in clinical trials. Control Clin Trials 1997;18:204-21
   PubMedGoogle Scholar
• Prasad S, Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007;23:379-94
   PubMed Web of Science ®Google Scholar
• Cheng JY, Chen RY, Ko JS, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007;194:197-209
   PubMed Web of Science ®Google Scholar
• Kraemer HC. Reporting the size of effects in research studies to facilitate assessment of practical or clinical significance. Psychoneuroendocrinology 1992;17:527-36
   PubMed Web of Science ®Google Scholar
• Gibson AP, Bettinger TL, Patel NC, et al. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 2006;40:1134-42
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Newcorn JH, Gao H, et al. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. J Am Acad Child Adolesc Psychiatry 2007;46:566-72
   PubMed Web of Science ®Google Scholar
• Faraone SV, Wilens TE. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 2007;68 (Suppl. 11):15-22
   PubMed Web of Science ®Google Scholar
• Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:21-31
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Faries DE, Moore RJ, et al. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008;95:140-6
   PubMed Web of Science ®Google Scholar
• Lile JA, Stoops WW, Durell TM, et al. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol 2006;14:136-47
   PubMed Web of Science ®Google Scholar
• Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry 2004;65 (Suppl. 3):38-45
   PubMed Web of Science ®Google Scholar
• Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008;12:248-53
   PubMed Web of Science ®Google Scholar
• Commission on Human Medicines (CMH) ad hoc Expert Advisory Group on Strattera (atomoxetine). Strattera (atomoxetine) – Risk:Benefit Assessment. London: Medicines and Healthcare products Regulatory Agency (MHRA) of the UK Department of Health, 2006. Available at: www.mhra.gov.uk/home/groups/es-foi/documents/foidisclosure/con2024013.pdf [Last Accessed 14 April 2009]
   Google Scholar
• Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension 2007;50:47-53
   PubMed Web of Science ®Google Scholar
• Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-84
   PubMed Web of Science ®Google Scholar
• Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005;9:275-89
   PubMedGoogle Scholar